Personalized briefing
Discovery of the day · Neurology
Association Between Neurofilament Light Chain and Real‐World Ambulatory Function in Progressive MS
Dear Damien Boorman, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology · Multiple Sclerosis
Discovery of the day
A post hoc analysis of the Phase III SPI2 trial demonstrates that serum neurofilament light chain (sNfL) is bidirectionally associated with real-world daily step count in a large progressive multiple sclerosis cohort, with higher sNfL predicting reduced ambulatory activity and vice versa. Among 506 participants, a 10% increase in daily steps corresponded to a 0.015 decrease in sNfL z-score (95% CI −0.022 to −0.008; p < 0.001), and each 1-SD increase in sNfL was associated with 141 fewer subsequent steps (β = −141; 95% CI −302 to 21; p = 0.088). This work directly advances the biomarker-to-function translation problem central to progressive MS management, and its use of passive wearable monitoring aligns with your interest in developing objective, ecologically valid outcome measures that can improve well-being at scale.
Novelty
82%
Rigor
88%
Significance
80%
Validity
84%
Clarity
86%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
